Use of dose–exposure–response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis

TY - JOUR

T1 - Use of dose–exposure–response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis

AU - Lebwohl, M.

AU - Langley, R. G.

AU - Zhu, Y.

AU - Zhou, H.

AU - Song, M.

AU - Shen, Y. K.

AU - Parnell Lafferty, K.

AU - Reich, K.

N1 - Funding Information: Funding sources This study was funded by Janssen Research & Development, LLC. The authors wish to thank Kristin Ruley Sharples, PhD, of Janssen Scientific Affairs, LLC, Spring House, PA and Cynthia Guzzo, MD, of Kelly Services, for their writing and editorial support in the preparation of this article. Publisher Copyright: © 2019 European Academy of Dermatology and Venereology

PY - 2019/11/1

Y1 - 2019/11/1

UR - http://www.scopus.com/inward/record.url?scp=85067689471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067689471&partnerID=8YFLogxK

U2 - 10.1111/jdv.15668

DO - 10.1111/jdv.15668

M3 - Article

C2 - 31077471

AN - SCOPUS:85067689471

SN - 0926-9959

VL - 33

SP - 2082

EP - 2086

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 11

ER -